-
1
Xu et al. review post-translational modifications (PTMs) in retinoblastoma, linking them to signaling, chromatin regulation, and immune interactions.
-
2
The integration of heterogeneous evidence streams in retinoblastoma research complicates the clinical prioritization of PTM-related observations.
-
3
Not all compounds affecting PTMs should be classified as PTM-targeting therapies; distinctions between direct and indirect effects are crucial.
-
4
Retinoblastoma therapy must consider survival, globe salvage, visual preservation, and ocular safety, emphasizing the need for local drug delivery.
-
5
PTM-immunotherapy combinations require retinoblastoma-specific validation due to variability in antigen expression and immune response.
